Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks

Abstract
Purpose To evaluate the anatomic–functional results and complications associated with the use of photodynamic therapy (PDT) with verteporfin in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Methods The authors retrospectively evaluated 10 consecutive patients (10 eyes) with CNV secondary to AS. All patients were treated with standard PDT with verteporfin protocol. The primary outcome to evaluate was the proportion of cases that lost 2 at baseline (SD 1.9, range 1.0–5.7 mm2) and 12.1 mm2 at the final examination (SD 15.1, range 0.8–50.6 mm2). One patient developed a subfoveal rip of the retinal pigment epithelium. In the control group, the mean duration of follow-up was 15 months (SD 2.4, range 12–18 months). At baseline, the mean VA was 20/160 (range 20/100–20/320) and the mean GLD was 2685 μm (SD 676.8, range 1800–3500 μm). At the last examination, mean VA was 20/640 (range: 20/400–20/800) and mean GLD was 5528 μm (SD 2106.90, range 3500–8000 μm). Conclusion PDT with verteporfin does not seem to be a good treatment for stabilization of VA and lesion size in CNV secondary to AS, although the overall results seem to be slightly better in the group of patients treated with PDT than in the control group.